Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
recreational and clinical use under prescription remains legal
ADA: Lilly makes its case for oral GLP-1 orforglipron A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer
Inflammation and oxidative stress in multiple sclerosis: consequences for therapy development
While these symptoms are nonspecific, they may indicate hypomagnesemia, especially in patients with chronic diarrhea, malabsorption, or poorly controlled diabetes
Cardiovascular symptoms to report within 24 hours : sustained resting heart rate above 100 bpm, home blood pressure readings above 150/95 mmHg on two consecutive measurements, dizziness on standing (suggesting orthostatic instability), or new-onset headache that differs from the patient's typical pattern
US$ 29.53
US$ 20.06
US$ 22.69
US$ 27.34
US$ 29.92
US$ 27.81
